Annotation
Umbilical cord blood transplantation
| The first 150 words of the full text of this article appear below. |
| |
Introduction |
|---|
Since Gluckman et al's first description of successful haemopoietic stem cell transplantation using umbilical cord blood (UCB) as the source of marrow progenitors in 1989,1 more than 500 umbilical cord blood stem cell transplants have been performed. Umbilical cord blood banks have been set up in the USA and Europe to store these cells, which in the past have been considered a waste product of reproduction. Although most UCB haemopoietic stem cell transplants have taken place in the past three years, recently published reports2-5 have given an important insight into the clinical potential of UCB as a source of haemopoietic progenitor cells for transplantation.
Allogeneic bone marrow transplantation (BMT) can potentially be used to
cure a variety of diseases including haematological malignancies, bone
marrow failure syndromes, haemoglobinopathies, immunodeficiencies, and
some inborn errors of metabolism.6 The use of allogeneic
BMT is limited by the need for adequate tissue matching of
This article has been cited by other articles:
-
JONES, C A, WARNER, J O
(1999). Umbilical cord blood transplantation. Arch. Dis. Child.
81: 278l-278
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



